ABEO News and Press, Abeona Therapeutics Inc. From 11/12/25

2025-11-12 07:33:36 ET More on Abeona Therapeutics Abeona Therapeutics: Zevaskyn Data Key In Gauging Momentum - Why I Hold Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript Abeona Therapeutics: AAV204 Capsid Could Be Next Growth Prospect Beyond Zevasky...

- First anticipated ZEVASKYN ® patient treatment shifted to 4Q 2025 following implementation of optimized release assay - - Strong and growing patient demand and treatment site network, along with broad market access provide foundation for sustainable commercial success -...

RWE AG ADR (RWEOY) is expected to report $0.16 for Q3 2025 Hillenbrand Inc (HI) is expected to report $0.62 for Q4 2025 Ardent Health Inc. (ARDT) is expected to report $0.42 for Q3 2025 Quince Therapeutics Inc. (QNCX) is expected to report $-0.2 for Q3 2025 GlobalFoundries Inc. (G...

2025-11-11 18:00:14 ET Major earnings expected before the bell on Wednesday include: Jumia Technologies AG ( JMIA ) Alcon ( ALC ) Gilat Satellite Networks Ltd. ( GILT ) On Holding AG ( ONON ) TransDigm Group Incorporated ( TDG ) Read the ful...

2025-11-11 11:39:12 ET More on Abeona Therapeutics Abeona Therapeutics: Zevaskyn Data Key In Gauging Momentum - Why I Hold Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript Abeona Therapeutics: AAV204 Capsid Could Be Next Growth Prospect Beyond Zevasky...

2025-11-10 09:52:22 ET ... Read the full article on Seeking Alpha For further details see: Abeona Therapeutics: ZEVASKYN Data Key In Gauging Momentum - Why I Hold

CLEVELAND, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Wednesday, November 12, 2025 at 8:30 a.m. ET to discuss its third quarter 2025 financial results and corporate progress. The conference call will be available...

CLEVELAND, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced that the Centers for Medicare and Medicaid Services (CMS) has established a permanent Healthc...

CLEVELAND, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the appointment of James A. Gow, MD, MBA, MS, MHCM, as the Senior Vice President, Head of Cli...

CLEVELAND, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced that its ABO-503 gene therapy for X-linked retinoschisis (XLRS) has been selected to particip...